Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

Avian or bird flu (H5N1) is a viral infection that spreads in birds, cows and other animals and can cause severe illness and at times, be fatal to humans in rare cases. Until now, the flu primarily affected wild aquatic birds including ducks, geese, gulls and poultry such as chickens as well as turkeys.

However earlier this month, a dairy cow in the Netherlands appears to have been contracted bird flu, making this the first time cattle outside of the United States has suffered the infection.

Previously, transmission of avian flu from cattle to humans has only been reported in the US among farm workers exposed to infected cattle or contaminated environments, and such cases remain sporadic and all developed only mild symptoms.

How Was The Cow Infected?

According to a detailed letter from the Dutch agriculture minister, a cat on a dairy farm in the province of Friesland died from H5N1 last month, which prompted officials to sample blood and milk from cattle at the farm.

Out of the 20 tested, one cow had antibodies to the virus in its milk but did not test positive for the virus itself. “There are also no signs of avian influenza spreading to other dairy farms,” the minister wrote.

The cow had mastitis and respiratory problems last month and its milk was not processed, the letter stated. Also, milk from the farm had been pasteurized, which inactivates the virus and prevents it being transmitted to humans.

“This means that there is very little chance that virus from the infected cow has ended up in the milk for human consumption,” the minister assured. It remains unclear how the virus arrived at the farm or how the cat and cow became infected.

Since October 2025, more than three dozen farms in the Netherlands have had outbreaks and over 1.5 million chickens, turkeys and ducks have been killed to stop the virus’ spread.

Is Bird Flu Dangerous For Humans?

The H5N1 strain drew worldwide concern in the early 2000s because of its high fatality rate in infected people. Although sustained human-to-human transmission is uncommon, infection can occur through close contact with sick or dead birds, their droppings, or contaminated environments.

Bird flu has posed major challenges for both the poultry industry and public health systems, with outbreaks often resulting in large-scale culling to limit the spread.

India has experienced recurring avian influenza outbreaks, particularly in regions with dense poultry farming. Even with strict control measures in birds, the risk of human infection persists, making awareness, hygiene practices, and preventive steps essential for protecting public health.

The common ways humans can contract the virus include:

• Direct contact with infected birds: Handling sick or dead birds, cleaning poultry farms, or working in live bird markets increases the risk
• Exposure to contaminated surfaces: The virus can survive on surfaces such as bird cages, equipment, and clothing. Touching these and then touching the eyes, nose, or mouth can lead to infection
• Consumption of undercooked poultry or eggs: While properly cooked poultry is safe, raw or undercooked meat and eggs from infected birds may pose a risk
• Airborne transmission in poultry farms: In rare cases, workers in enclosed spaces with infected birds may inhale tiny virus-laden particles

In a breakthrough study, a group of Spanish researchers have created a drug-based cure that can kill pancreatic cancer tumors in the body and eliminate the disease completely.

A study from the Spanish National Cancer Research Centre (CNIO) found that a combination of three drugs, known as CNIO therapy, can shut down multiple tumor survival mechanisms at the same time, preventing the cells from the rewiring themselves and defeating the treatment

Led by renowned cancer biologist Dr Mariano Barbacid, the authors wrote of the results: 'These studies open a way to design new combination therapies that can improve the survival of patients with pancreatic ductal adenocarcinoma. These results set the direction for the development of new clinical trials."

How Does The Drug Work?

To overcome cancer's ability to block the effects of singular therapy drugs, Dr Barbacid’s team attempted attacking the cancerous tumors from three directions together.

The first drug, daraxonrasib, blocked the main KRAS signal that drives tumor growth while the second drug, afatinib, shut down EGFR and HER2, both pathways that cancer cells often use to escape KRAS-targeted treatment.

The third drug, SD36, stopped the functioning of bSTAT3, a backup system that helps cancer cells survive stress and resist therapy.

In the mice study, when scientists combined and used all three drugs together in the rodents, they saw the pancreatic tumours shrank completely and did not return, even more than 200 days after treatment stopped.

The same effect was seen in genetically engineered mouse models and in tumors taken from human patients that were grown in a laboratory. The animals who underwent CNIO therapy did not show serious side effects, suggesting the combination could be safe enough to test in humans.

Despite promising results, the authors advised caution and noted: ""We are not yet in a position to carry out clinical trials with triple therapy. The authors themselves warn that optimising this combination for patients will be a complex process, although they are confident that the finding will set the course for future trials."

Pancreatic Cancer: All You Need To Know

While there are no clear signs of early pancreatic cancer, symptoms begin to show once the disease reaches the digestive system. Some of these include:

• Jaundice (yellowing of your skin).
• Dark urine
• Light-colored stool
• Upper abdominal pain
• Middle back pain
• Fatigue
• Itchy skin
• Nausea and vomiting
• Gas or bloating
• Lack of appetite
• Blood clots
• Weight loss
• New-onset diabetes

Certain prominent risk factors include smoking cigarettes, cigars and using other forms of tobacco; obesity; Type 2 diabetes and genetic factors.

Pancreatic cancer is also resistant to many common cancer drugs and it notoriously difficult to treat, making this discovery exceptionally important in the search for a permanent cure.

About 22,000 new cases of pancreatic cancer are estimated to occur annually in India out of which nearly 13,000 die from the cause, making it the 24th most common cancer in India.

A collective of environmental and public health researchers has raised serious concerns over free-living amoebas, warning that these organisms could become an increasing global health risk. Their concern stems from the amoebas’ ability to survive in harsh conditions and bypass routine water treatment processes.

These tiny protozoa occur naturally in soil and freshwater and are usually harmless. However, certain species, particularly Naegleria fowleri, widely referred to as the “brain-eating amoeba,” can trigger rare but deadly infections when contaminated water enters the nose during activities such as swimming or diving.

This issue is especially significant for India, as Naegleria fowleri causes primary amoebic meningoencephalitis (PAM), a fatal condition that has seen repeated outbreaks in states such as Kerala.

What Is Naegleria Fowleri?

Naegleria fowleri is a free-living ameba, meaning it is a single-celled organism that survives independently in the environment. It flourishes in warm freshwater sources such as lakes, rivers, ponds, and hot springs. Commonly labelled the “brain-eating ameba,” it earns this name because of its ability to infect the brain and damage brain tissue. The organism is found worldwide in soil and warm freshwater bodies.

On rare occasions, it has also been detected in inadequately maintained swimming pools, splash pads, and other recreational water facilities. In some instances, the ameba has even been identified in tap water.

According to the US Centers for Disease Control and Prevention (CDC), when water containing the ameba enters the nose and reaches the brain, it can lead to an infection known as primary amebic meningoencephalitis (PAM). In the United States, PAM affects fewer than 10 people each year. Almost everyone diagnosed with PAM does not survive. From 1962 to 2024, 167 cases were reported in the US, with only four known survivors.

What Is Primary Amebic Meningoencephalitis?

Primary Amebic Meningoencephalitis (PAM) is a rare but almost always fatal brain infection caused by the Naegleria fowleri amoeba, often called the “brain-eating amoeba.” The organism enters the body through the nose from warm freshwater or soil, travels to the brain, and destroys brain tissue. This leads to intense inflammation, confusion, seizures, and, in most cases, death within days of the onset of severe symptoms.

Primary Amebic Meningoencephalitis Signs And Symptoms

Early signs of PAM may include headache, fever, nausea, and vomiting. The disease progresses very quickly. Most patients die within one to 18 days after symptoms appear, with coma and death often occurring within five days. As the infection advances, symptoms can worsen to include a stiff neck, confusion, reduced awareness of people and surroundings, loss of balance, and hallucinations.

Brain Eating Amoeba Can Thrive In Heat

In a recent perspective published in the journal Biocontaminant, scientists led by Longfei Shu from Sun Yat-sen University explain how climate change, ageing infrastructure, and poor monitoring systems are creating conditions that allow these microbes to spread into areas where they were previously uncommon. Some species are capable of surviving high temperatures and can withstand disinfectants such as chlorine, making them particularly difficult to remove from drinking water supplies and distribution systems.

Adding to the concern, free-living amoebas can serve as protective carriers for harmful bacteria and viruses, housing them inside their cells and helping them spread. This so-called “Trojan horse” effect has raised fresh questions about water safety and how pathogens move through the environment, highlighting the need for coordinated, One Health-based approaches.

Experts warn that without strong intervention and improved water management policies, free-living amoebas could emerge as a major and largely overlooked threat to global public health in the coming years.